Clinical Trial

CIK in Treating Patients With Bladder Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 22, 2016 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Chemotherapy is the main treatment method for patients with Bladder Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Bladder Cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2015-07-01; most recent amendment 2016-02-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-02-18
Trial Details
NCT Number NCT02489890
Lead Sponsor The First People's Hospital of Changzhou
Conditions Urinary Bladder Neoplasms
Enrollment 1,500 participants
Start Date 2016-02
Primary Completion 2025-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2016-02-22